13959-53-0

Basic information

• Product Name: 4-nitro-3-phenoxypyridine-N-oxide
• Synonyms: 4-nitro-3-phenoxypyridine-N-oxide
• CAS NO: 13959-53-0
• Molecular Weight: 232.196
• Mol File: 13959-53-0.mol

Chemical Properties

• CAS DataBase Reference: 4-nitro-3-phenoxypyridine-N-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-nitro-3-phenoxypyridine-N-oxide(13959-53-0)
• EPA Substance Registry System: 4-nitro-3-phenoxypyridine-N-oxide(13959-53-0)

Safety Data

• Hazardous Substances Data: 13959-53-0(Hazardous Substances Data)

Upstream product

• 769-54-0 3-fluoro-4-nitropyridine N-oxide 
• 108-95-2 phenol 
• 2402-97-3 3-bromopyridine N-oxide 
• 626-55-1 3-Bromopyridine 
• 1678-49-5 3-Bromo-4-nitropyridine N-oxide 
• 139-02-6 sodium phenoxide 

Downstream Products

• 132038-33-6 4-amino-3-phenoxypyridine 
• 180194-87-0 4-amino-3-phenoxypyridine-N-oxide 

Relevant articles and documents

COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention concerns compounds comprising N-methyl-2-pyridone, and pharmaceutically-acceptable salts and compositions of such compounds. Such compounds are useful in anti-inflammatory and anti-cancer therapies. Therefore, the present invention also concerns such compounds for use as medicaments, particularly for the treatment of inflammatory diseases and oncology.

Spectral and crystallographic study of pyridinic analogues of nimesulide: Determination of the active form of methanesulfonamides as COX-2 selective inhibitors

Compound 7, N-(3-phenoxy-4-pyridinyl)trifluoromethanesulfonamide, showed in vitro (whole blood assay) a strong inhibitory activity on the two cyclooxygenase (COX) enzymes (IC50(COX1) = 2.2 μM and IC50(COX-2) = 0.4 μM), being more act

Synthesis and pharmacological evaluation of derivatives structuraily related to nimesulide

The present work reports the synthesis of a series of compounds structurally related to the antiinflammatory and antihistaminic agent nimesulide (I), in which the p-nitrophenyl moiety has been replaced by pyridine (1a-c) and pyridine N-oxide (2a-c). In addition, two compounds (3a, 4a) have been synthesized in which the p-nitro group of I was substituted by a cyano and a 1H-tetrazol-5-yl group, respectively. Representative 1a and 2a were also modified by replacing the methanesulfonamido group with an acetamido group (5a, 6a). The pharmacological evaluation of compounds 1-6 in comparison to I, indicates that such modifications are detrimental to the activity. Moreover 3a and 4a caused bronchoconstriction and hypotension, thus behaving as histaminic-like rather then antihistaminic agents.

Phenoxypyridinamine compounds which are use as a dermatological composition

There are described compounds of the formula STR1 where n is 0 or 1; X is hydrogen, loweralkyl, loweralkoxy, halogen, formyl, loweralkylcarbonyl, loweralkyoxycarbonyl, loweralkoxycarbonylloweralkyl or hydroxymethyl; Y is hydrogen or halogen;and R is hydro